These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 10107734)

  • 21. Intellectual property. Decision on NFkappaB patent could have broad implications for biotech.
    Garber K
    Science; 2006 May; 312(5775):827. PubMed ID: 16690824
    [No Abstract]   [Full Text] [Related]  

  • 22. Biotech boom.
    Jayaraman KS
    Nature; 2005 Jul; 436(7050):480-3. PubMed ID: 16049469
    [No Abstract]   [Full Text] [Related]  

  • 23. Footing the bill: should we all have to pay for one company's bright idea?
    Nowak R; Concar D
    New Sci; 2002 May; 174(2343):4-5. PubMed ID: 12731532
    [No Abstract]   [Full Text] [Related]  

  • 24. Putting your best mode forward.
    Tsao YR; Tabtiang RK
    Nat Biotechnol; 2000 Oct; 18(10):1113-4. PubMed ID: 11017054
    [No Abstract]   [Full Text] [Related]  

  • 25. Generics battle brand names over mortality of drug patents.
    Betz R
    J Healthc Resour Manag; 1995 Jul; 13(7):35-7. PubMed ID: 10144008
    [No Abstract]   [Full Text] [Related]  

  • 26. University-industry collaboration. Last of the big-time spenders?
    Lawler A
    Science; 2003 Jan; 299(5605):330-3. PubMed ID: 12531991
    [No Abstract]   [Full Text] [Related]  

  • 27. Hatch-waxman changes debated.
    Chahine K
    Nat Biotechnol; 2000 Jul; 18(7):710-1. PubMed ID: 10888831
    [No Abstract]   [Full Text] [Related]  

  • 28. Biotech jostles with pharma for slice of HIV market.
    Katsnelson A
    Nat Biotechnol; 2006 Jan; 24(1):3-4. PubMed ID: 16404375
    [No Abstract]   [Full Text] [Related]  

  • 29. The emerging effects of the Drug Price Competition and Patent Term Restoration Act of 1984.
    Lewis RA
    J Contemp Health Law Policy; 1992; 8():361-78. PubMed ID: 10118987
    [No Abstract]   [Full Text] [Related]  

  • 30. A generic problem.
    Hanauer SB
    Nat Clin Pract Gastroenterol Hepatol; 2006 Dec; 3(12):649. PubMed ID: 17130869
    [No Abstract]   [Full Text] [Related]  

  • 31. Patent crunch pending.
    Wadman M
    Nature; 2007 Oct; 449(7163):651. PubMed ID: 17968400
    [No Abstract]   [Full Text] [Related]  

  • 32. Companies balk at California's patent rules for stem cell research.
    Keim B
    Nat Med; 2007 Jan; 13(1):6. PubMed ID: 17206112
    [No Abstract]   [Full Text] [Related]  

  • 33. Biotech patents and the inequitable conduct doctrine.
    Michael A
    Nat Biotechnol; 2006 Oct; 24(10):1219-21. PubMed ID: 17033655
    [No Abstract]   [Full Text] [Related]  

  • 34. Wrong map: why public science can't really be public.
    Mukherjee S
    New Repub; 2000 May; 222(19):14-5. PubMed ID: 12465651
    [No Abstract]   [Full Text] [Related]  

  • 35. Equivalents in biotechnology patents.
    Auer HE
    Nat Biotechnol; 2003 Mar; 21(3):329-31. PubMed ID: 12610574
    [No Abstract]   [Full Text] [Related]  

  • 36. Biotech patents: looking backward while moving forward.
    Eisenberg RS
    Nat Biotechnol; 2006 Mar; 24(3):317-9. PubMed ID: 16525404
    [No Abstract]   [Full Text] [Related]  

  • 37. Private biotech 2004--the numbers.
    Hodgson J
    Nat Biotechnol; 2006 Jun; 24(6):635-41. PubMed ID: 16763589
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Negotiating the RNAi patent thicket.
    Schmidt C
    Nat Biotechnol; 2007 Mar; 25(3):273-5. PubMed ID: 17344871
    [No Abstract]   [Full Text] [Related]  

  • 39. State of biotech sector--2005.
    Lawrence S
    Nat Biotechnol; 2006 Jun; 24(6):603. PubMed ID: 16763577
    [No Abstract]   [Full Text] [Related]  

  • 40. 2007--a banner year for biotech.
    Lawrence S
    Nat Biotechnol; 2008 Feb; 26(2):150. PubMed ID: 18259162
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.